Hypoglycemic Coma in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib.
10.3904/kjm.2014.87.4.501
- Author:
Meyoung CHO
1
;
Hyeok SHIM
;
Moo Rim PARK
Author Information
1. Department of Internal Medicine, Gunsan Medical Center, Gunsan, Korea.
- Publication Type:Case Report
- Keywords:
Sunitinib;
Hypoglycemia;
Metabolic encephalopathy
- MeSH:
Brain Diseases, Metabolic;
Carcinoma, Renal Cell*;
Coma*;
Diabetes Mellitus, Type 2;
Humans;
Hypoglycemia;
Protein-Tyrosine Kinases
- From:Korean Journal of Medicine
2014;87(4):501-504
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We present a patient with type 2 diabetes mellitus and metastatic renal cell carcinoma who developed severe hypoglycemia and metabolic encephalopathy after sunitinib treatment. Sunitinib, a multi-target tyrosine kinase inhibitor, is used to treat metastatic renal cell carcinoma. Sunitinib-induced hypoglycemia has been reported and there are rare case reports of severe hypoglycemia due to sunitinib. Therefore, glycemic control should be monitored closely in diabetic patients treated with sunitinib.
